NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)
October 9, 2007
Study Finds NSF More Common Than Previously Reported | www.dimag.com
Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost no release of gadolinium may be a solution: gadoxetic acid, sold in Europe and Asia as Primovist.
IMDS - CTML - Value without contrast agents?
May 14, 2007
Imaging Diagnostic Systems Breast Scanner Performance Upgrade Program Nearing Completion | www.medicalnewstoday.com
The recent upgrade of the Computed Tomography Laser Mammography (CTLM(R)) system will only added minor details. The question whether this system without any contrast agent is of any value has not been answered so far.
Impropved pancreatic duct imaging in MR - small market for Secretin
May 14, 2007
Repligen Reports Positive Phase 2 Clinical Trial Results Of Secretin For MRI Imaging Of The Pancreas | www.medicalnewstoday.com
Pancreatic duct imaging is currently done with a heavily weighted T2 sequence that requires water in the duct for imaging. Increased production of pancreatic juice may make imaging easier. This is however a very small niche market which by itself will not allow survival of RG1068.
Page : 11 to 3 of 3
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011